Mustang Bio
Mustang Bio is dedicated to developing next-generation cell and gene therapies for difficult-to-treat cancers. They focus on translating recent breakthroughs in cell therapy into potential cures, partnering with leading academic institutions, and in-licensing first-in-class therapeutic candidates. Their mission is to bring hope to patients worldwide through innovative treatments and advanced manufacturing capabilities.
Industries
Nr. of Employees
medium (51-250)
Mustang Bio
Products
IL13Rα2-targeted CAR T investigational therapy (clinical candidate)
A CAR T cell therapy candidate directed at the IL13Rα2 tumor antigen for treatment of high-grade glioma and related central nervous system tumors.
CD20-targeted CAR T investigational therapy (clinical candidate)
A CD20-directed CAR T cell therapy candidate optimized for B-cell non-Hodgkin lymphoma and related B-cell malignancies.
Oncolytic herpes simplex virus investigational therapy (clinical candidate)
A replication-competent oncolytic herpes simplex virus platform developed to selectively replicate in tumor cells and induce oncolysis.
Combination CAR T plus oncolytic virus investigational program
A combination approach pairing CAR T cell therapy with an oncolytic virus intended to modify the tumor microenvironment and enhance CAR T efficacy.
MB-106
CD20 CAR autologous T cells engineered for patients with relapsed or refractory B cell non-Hodgkin lymphomas.
MB-101
IL-13Ralpha2-targeted CAR-T cell immunotherapy for the treatment of glioblastoma (GBM).
IL13Rα2-targeted CAR T investigational therapy (clinical candidate)
A CAR T cell therapy candidate directed at the IL13Rα2 tumor antigen for treatment of high-grade glioma and related central nervous system tumors.
CD20-targeted CAR T investigational therapy (clinical candidate)
A CD20-directed CAR T cell therapy candidate optimized for B-cell non-Hodgkin lymphoma and related B-cell malignancies.
Oncolytic herpes simplex virus investigational therapy (clinical candidate)
A replication-competent oncolytic herpes simplex virus platform developed to selectively replicate in tumor cells and induce oncolysis.
Combination CAR T plus oncolytic virus investigational program
A combination approach pairing CAR T cell therapy with an oncolytic virus intended to modify the tumor microenvironment and enhance CAR T efficacy.
MB-106
CD20 CAR autologous T cells engineered for patients with relapsed or refractory B cell non-Hodgkin lymphomas.
MB-101
IL-13Ralpha2-targeted CAR-T cell immunotherapy for the treatment of glioblastoma (GBM).
Services
End-to-end GMP-like manufacturing services including cleanroom processing, QC testing, and process development support for autologous cell therapies.
Evaluation, in-licensing and co-development of academic cell and gene therapy assets, plus management of collaborative agreements with clinical centers.
End-to-end GMP-like manufacturing services including cleanroom processing, QC testing, and process development support for autologous cell therapies.
Evaluation, in-licensing and co-development of academic cell and gene therapy assets, plus management of collaborative agreements with clinical centers.
Expertise Areas
- Autologous CAR T cell therapy development
- Oncolytic virus therapeutics
- Clinical trial management for early‑phase oncology studies
- Cell therapy manufacturing and process scale-up
Key Technologies
- Chimeric antigen receptor (CAR) T-cell therapy
- Oncolytic herpes simplex virus platforms
- Leukapheresis and autologous cell collection
- Ex vivo cell engineering and expansion
News & Updates
Fierce Biotech reports that Mustang Bio and City of Hope's CAR-T therapy has shown to extend survival in a phase 1 glioblastoma trial.
BioSpace reports that Mustang Bio announced the publication of data from their Phase 1 trial of MB-101 IL13Rα2-targeted CAR T-Cells in high-grade glioma in Nature Medicine.
MarketWatch reports that City of Hope's CAR T cell therapy has shown clinical activity in patients with aggressive brain tumors in a phase 1 trial.
Worcester Business Journal reports that Mustang Bio received FDA clearance for a combined brain tumor treatment.
CGTLive reports that Mustang Bio's CAR/Oncolytic Virus combo has been cleared for a glioblastoma/astrocytoma trial.
Healio / HemOnc Today reports that MB-106 induces responses in indolent lymphoma.
Fierce Biotech reports that Mustang Bio and City of Hope's CAR-T therapy has shown to extend survival in a phase 1 glioblastoma trial.
BioSpace reports that Mustang Bio announced the publication of data from their Phase 1 trial of MB-101 IL13Rα2-targeted CAR T-Cells in high-grade glioma in Nature Medicine.
MarketWatch reports that City of Hope's CAR T cell therapy has shown clinical activity in patients with aggressive brain tumors in a phase 1 trial.
Worcester Business Journal reports that Mustang Bio received FDA clearance for a combined brain tumor treatment.
CGTLive reports that Mustang Bio's CAR/Oncolytic Virus combo has been cleared for a glioblastoma/astrocytoma trial.
Healio / HemOnc Today reports that MB-106 induces responses in indolent lymphoma.